Skip Navigation

Cardiovascular Research 2007 76(1):5-7; doi:10.1016/j.cardiores.2007.07.011
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hébert, T. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hébert, T. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2007, European Society of Cardiology

Anti-β1AR antibodies in dilated cardiomyopathy: Are these a new class of receptor agonists?

Terence E. Hébert*

Department of Pharmacology and Therapeutics, Faculty of Medicine, 13th floor, Room 1303, McIntyre Medical Sciences Building, 3655 Promenade Sir William Osler, Montreal, QC, Canada H3G 1Y6

*Tel.: +1 514 398 1398; fax: +1 514 398 6690. terence.hebert@mcgill.ca

Received 5 July 2007; accepted 18 July 2007

The first 10% of the full text of this article appears below.

See article by Tutor et al.[9](pages 51–60) in this issue.


   1. Introduction
 
Under physiological conditions, the β1-adrenergic receptor (β1AR) is the predominant βAR responsible for inotropic, chronotropic and lusitropic responses in the myocardium via the classical Gs/adenylyl cyclase/PKA pathway (reviewed in [1–3]). However, during the development of heart failure, sustained β1AR signalling may also lead to a number of adverse effects including cardiomyocyte hypertrophy and eventually apoptosis. It has become clear in recent years that alterations in the ERK and other MAP kinase signalling cascades play critical and complicated roles in the development of cardiac hypertrophy and the progression towards heart failure [4]. It is also clear that β-adrenergic receptors are key . . . [Full Text of this Article]


   2. Anti-receptor antibodies and ERK signalling
 

   3. Interactions between anti-receptor antibodies and ligands
 

   4. Questions remaining
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?